Wall Street brokerages expect Leap Therapeutics Inc (NASDAQ:LPTX) to announce ($0.40) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Leap Therapeutics’ earnings. Leap Therapeutics posted earnings of ($0.45) per share during the same quarter last year, which indicates a positive year over year growth rate of 11.1%. The business is scheduled to announce its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that Leap Therapeutics will report full-year earnings of ($1.62) per share for the current fiscal year, with EPS estimates ranging from ($1.64) to ($1.59). For the next year, analysts anticipate that the firm will post earnings of ($1.65) per share, with EPS estimates ranging from ($1.89) to ($1.40). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Leap Therapeutics.
Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Wednesday, May 15th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.06).
Shares of LPTX stock traded up $0.03 on Friday, hitting $1.53. The stock had a trading volume of 187,728 shares, compared to its average volume of 716,082. The company has a market cap of $34.43 million, a P/E ratio of -0.61 and a beta of 2.13. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.77 and a quick ratio of 2.77. Leap Therapeutics has a 12-month low of $1.35 and a 12-month high of $9.45.
A number of hedge funds and other institutional investors have recently bought and sold shares of LPTX. Virtu Financial LLC purchased a new stake in Leap Therapeutics during the fourth quarter worth about $28,000. BlackRock Inc. boosted its position in Leap Therapeutics by 57.3% during the first quarter. BlackRock Inc. now owns 24,451 shares of the company’s stock worth $45,000 after purchasing an additional 8,906 shares during the period. Deutsche Bank AG boosted its position in Leap Therapeutics by 45.7% during the fourth quarter. Deutsche Bank AG now owns 124,338 shares of the company’s stock worth $248,000 after purchasing an additional 39,000 shares during the period. FMR LLC boosted its position in Leap Therapeutics by 3.9% during the fourth quarter. FMR LLC now owns 957,124 shares of the company’s stock worth $1,914,000 after purchasing an additional 36,300 shares during the period. Finally, Vanguard Group Inc boosted its position in Leap Therapeutics by 23.2% during the third quarter. Vanguard Group Inc now owns 256,268 shares of the company’s stock worth $1,997,000 after purchasing an additional 48,300 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Recommended Story: How to Profit and Limit Losses With Stop Orders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.